Hypersensitivity to cephalosporins, penicillins, carbapenems.
There is a synergistic antibacterial effect when used simultaneously with aminoglycoside antibiotics. Increases the nephrotoxicity of loop diuretics and aminoglycosides, prolongs the effect of alcohol (causes a disulfiram-like reaction). Aminoglycosides increase the antibacterial activity. Probenecid slows down the elimination of the drug, doubles the duration of action. Anticoagulants, thrombolytics, and NSAIDs increase the risk of bleeding. Pharmacologically incompatible with solutions of aminoglycosides (can not be mixed in one syringe).
From the cardiovascular system and blood (hematopoiesis, hemostasis): leukopenia, thrombocytopenia, neutropenia, thrombophlebitis (with intravenous administration).
From the gastrointestinal tract: nausea, vomiting, pseudomembranous colitis, persistent hepatitis, cholestatic jaundice, dysbiosis.
Allergic reactions: skin rash, urticaria, eosinophilia, drug fever, in rare cases-bronchospasm, Quincke's edema, anaphylactic shock.
Other: superinfection, pain and infiltration in place of the/m introduction, positive Coombs ' test, reducing Cl creatinine, increased urea nitrogen in blood (in patients with renal insufficiency), transient increase in liver transaminases and alkaline phosphatase.
Abdominal and gynecological infections, sepsis, meningitis, endocarditis, urinary tract infections, bone, joint, skin and soft tissue infections. Prevention of postoperative infectious complications.
It has a wide spectrum of antibacterial action. It is active against many Gram-negative and Gram-positive microorganisms: Escherichia coli, Enterobacter spp., Klebsiella spp. (may become resistant), Haemophilus influenzae, Proteus mirabilis, Providencia rettgeri, Morganella morganii, some strains of Proteus vulgaris, Staphylococcus aureus (including penicillinase-producing and methicillin-resistant strains), Staphylococcus epidermidis, Streptococcus spp., Gram-positive and gram-negative anaerobes (Peptococcus spp., Peptostreptococcus spp., Clostridium spp., Bacteroides spp., Fusobacterium spp.).
After intravenous administration at a dose of 0.5 or 1 g Cmax it is reached after 30-120 minutes and is 13 mcg/ml and 25 mcg / ml, respectively. With intravenous administration of 1, 2 and 3 g after 10 minutes, the plasma concentration is 139, 240 and 533 mcg/ml (at the therapeutic level, it remains for 6 hours). T1/2 after intravenous administration — 32 min, after intravenous administration — 60 min. Therapeutic concentrations are created in pleural and articular fluids, bile, and bones. It is excreted in the urine in unchanged form (65-85% is excreted in 8 hours). After intravenous administration of 0.5 and 1 g, the content in the urine is 254 and 1357 mcg/ml, with intravenous administration at a dose of 1 and 2 g-750 and 1380 mcg/ml, respectively. In the case of renal failure, the elimination of the drug slows down.
In a dry place, protected from light, at a temperature of 15-25 °C.
Keep out of reach of children.
Shelf life of the drug Cefat®2 года.Do not use after the expiration date indicated on the package.
| Powder for the preparation of an injectable solution for intravenous administration | 1 fl. |
| cefamandol | 0.5 or 1 g |
in a pack of cardboard 1 or 10 bottles, or in a box of 50 bottles.
| Powder for the preparation of an injectable solution for intramuscular administration | 1 fl. |
| cefamandol | 0.5 or 1 g |
there are 50 vials in a box.
It is possible if the expected effect of the therapy exceeds the potential risk to the fetus or newborn.
V / m or v / v. For intravenous administration, the drug (0.5 or 1 g) is dissolved in 3 ml of water for injection or in 3 ml of isotonic sodium chloride solution. For intravenous administration, dissolve 1 g of the drug in 10 ml of water for injection or in 10 ml of isotonic sodium chloride solution. For intravenous drip administration, the dissolved drug is mixed with a 10% glucose solution or an isotonic sodium chloride solution.
Adults-0.5-1 g every 4-8 hours, for diseases of the urinary tract-0.5 g (in severe cases — 1 g) every 8 hours, for severe infections-up to 2 g every 4 hours (12 g/day). Children — 50-150 mg / kg / day (in severe infections-up to 150 mg/kg/day) with an interval between injections-4-8 hours. For infections caused by beta-hemolytic streptococcus, treatment is continued for at least 10 days. For the prevention of postoperative infectious complications, 1-2 g is administered to adults 30-60 minutes before the intervention, and 50-100 mg/kg to children, followed by the same doses for 24-48 hours.
In case of impaired renal function, the dosage regimen is set taking into account Cl creatinine. The first dose is the same for all patients and is 1-2 g. With a creatinine Cl of 50-80 ml / min: for the treatment of severe infections-2 g every 4 hours, for the treatment of moderate infections-1.5 g every 6 hours or 2 g every 8 hours. With a creatinine Cl of 25-50 ml / min: for the treatment of severe infections-1.5 g every 4 hours or 2 g every 6 hours, for the treatment of moderate infections-1.5 g every 8 hours. With a creatinine Cl of 10-25 ml / min: for the treatment of severe infections-1 g every 6 hours or 1.25 g every 8 hours, for the treatment of moderate infections-1 g every 8 hours. With a creatinine Cl of 2-10 ml / min: for the treatment of severe infections-670 mg every 8 hours or 1 g every 12 hours, for the treatment of moderate infections-500 mg every 8 hours or 750 mg every 12 hours. With a creatinine Cl of less than 2 ml / min: for the treatment of severe infections-500 mg every 8 hours or 750 mg every 12 hours, for the treatment of moderate infections-500 mg every 12 hours. Patients on hemodialysis — intravenous or intravenous 1 g every 12 hours (if administered intravenously, then after completion of hemodialysis, an additional 1/3–1/2 dose is administered).
J01DC03 of Cefamandol
